Endowed Chair: Precision Therapeutics in Oncology and Pharmacogenomics Program led by Anish Ray, M.D.
Cook Children's has awarded Anish Ray, M.D., an Endowed Chair to establish and expand the Precision Therapeutics in Oncology and Pharmacogenomics Program. This transformative program will enhance our expertise in precision therapeutics within pediatric oncology and expand our pharmacogenomics service, aiming to optimize precision therapeutics for children with cancer, enabling more effective, individualized treatment plans. It will empower clinicians and families alike to embrace individualized health management through precision health equity. The program will also accelerate precision research efforts, in precision oncology, advancing our ability to provide tailored therapies that improve patient outcomes. The Cook Children's Precision Therapeutics in Oncology and Pharmacogenomics Program will pioneer innovative treatments that significantly improve the lives of children facing cancer with a genetic basis.
Meet Dr. Ray
Dr. Ray is passionate about elevating the standard of care for personalized pediatric cancer treatment by advancing research, targeted therapy and data driven treatment plans.
- Targeted approach to Langerhans Cell Histiocytosis (LCH) using MEK inhibitor, Trametinib: https://www.clinicaltrials.gov/study/NCT06582745?intr=trametinib&rank=9
- Precision Medicine Registry
Peer Reviewed Articles
- Kumar, S., Gonzalez, A., Farbo, D., Albritton, K., Ray, A. “The effects of proton and photon radiation therapy on the development of pediatric dermatitis”. Radiation, November, 2024.
- Ray, A., Levitt, M., Efunkoya T., Trinkman H. “Precision Medicine in Acute Lymphoblastic leukemia”. Children, November, 2024. https://doi.org/10.20944/preprints202410.0191.v1
- Zumwalt, L., Schluterman H., Ray, A. “Role of medical students in a pediatric oncology precision medicine clinic”. BMC Medical Education, December, 2024.
- Zumwalt, L., Schluterman H., Ray, A. “Life-threatening lymphatic malformation with somatic activating NRAS mutation successfully treated with trametinib: a case study”. Journal of Pediatric Hematology/Oncology, January, 2025.
- Wojciechowska N, Orr K, Ray A. Immune Checkpoint Inhibition in Pediatric Oncology Patients: A Single-Institution Experience. Hemato 2024; 5(1): 66-80
- Wojciechowska N, Burke S, Ray A. “MEK Inhibition in the Treatment of Congenital Langerhans Cell Histiocytosis: A Case Report and Review of the Literature” J Pediatr Hematol Oncol 2024;46:383–387
Poster Presentations
- A Ray, H Trinkman, D Carrasco, L Hamilton. Precision medicine program at Cook Children’s Medical Center: Early days. Accepted for poster presentation at ASPHO, 2025.
- L Hamilton, H Trinkman, W Stigall, A Hoeft, A Ray. Precision medicine as a service: Cook Children's Precision Medicine Program. TCU Faculty Research Symposium, 2024.
- Wojciechowska N, Murray L, Aguilar R, Ray A. Immunotherapy in Pediatrics. Accepted for presentation at: American Society of Pediatric Hematology and Oncology Conference; 2024 Apr 3-6; Seattle, WA
- Wojciechowska N, Murray L, Aguilar R, Ray A. Osteoblastoma: A Case Series. Accepted for presentation at: American Society of Pediatric Hematology and Oncology Conference; 2024 Apr 3-6; Seattle, WA
- Wojciechowska N, Burke S, Ray A. Congenital Multi-system Langerhans Cell Histiocytosis Responding to Targeted Therapy with Trametinib. Accepted for presentation at: American Society of Pediatric Hematology and Oncology Conference; 2024 Apr 3-6; Seattle, WA
- Orr K, Rotolo S, Jernigan H, Koentz M, Wojciechowska N, Ray A. Creation of a Tumor Molecular Testing Registry: An Update. Accepted for presentation at: American Society of Pediatric Hematology and Oncology Conference; 2024 Apr 3-6; Seattle, WA
- Keane M, Wojciechowska N, Ray A. Role of Medical Students in a Pediatric Oncology Precision Medicine Clinic. Accepted for presentation at: American Society of Pediatric Hematology and Oncology Conference; 2024 Apr 3- 6; Seattle, W
- Wojciechowska N, Diaz M, Ray A. Children with Langerhans Cell Histiocytosis Treated with MEK Inhibitor, Trametinib, Front-line and at Relapse. Accepted for presentation at: 40th Annual Meeting of the Histiocytes Society; 2024 Nov 6-9; Goa, India
Oral Presentations
- A Ray, K Orr, N Wojciechowska, H Trinkman, L Hamilton. Precisely! Precision medicine and pharmacogenomics at Cook Children's. Presented at Pediatric Grand Rounds, 2024.
$50,000 – Blue Peaks Giving Circle; Genomic Investigative Functional Testing and Treatment Fund
Meet our researchers
Luke Hamilton, Manager, Research Data Science and Analytics | Precision Medicine Research
I was born in Irving, Texas where I attended high school and met my wife. We moved to Abilene, Texas to attend Hardin-Simmons University where I completed my bachelor's degree. I then attended the University of North Texas Health Science Center where I earned my master's degree. Prior to working at Cook Children's, I worked as a scientist in an immunogenomics laboratory where I developed TCR-mimic antibodies, and a pain management medical device company where I developed a three dimensional skin simulator used to visualize radiofrequency ablations. While at Cook Children's, I have worked as a clinical scientist for endocrinology and genetics, and have authored over 25 publications and written 2 textbook chapters. Outside of work, I enjoy spending time with my wife and two boys and staying active through running, weight training, and hiking.
Google Scholar: Luke Hamilton - Google Scholar
Related information
- Oncology Pharmacology at Cook Children's (cookchildrens.org)
- Targeted Therapy Paves Way for LCH Patient | Mighty Makenzie | Co...
Support this research
Be part of the innovative and life-changing work we're doing at Cook Children's. Support the Endowed Chair Program today.